AbbVie is a drug manufacturers - general business based in the US. AbbVie shares (ABBV) are listed on the NYSE and all prices are listed in US Dollars. AbbVie employs 50,000 staff and has a trailing 12-month revenue of around $54.4 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $173.61 |
|---|---|
| 52-week range | $132.11 - $179.55 |
| 50-day moving average | $166.20 |
| 200-day moving average | $162.40 |
| Wall St. target price | $184.72 |
| PE ratio | 51.2857 |
| Dividend yield | $6.06 (3.6%) |
| Earnings per share (TTM) | $3.36 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $173.61 from 2024-07-22
| 1 week (2024-07-16) | 2.61% |
|---|---|
| 1 month (2024-06-21) | 1.89% |
| 3 months (2024-04-23) | 2.40% |
| 6 months (2024-01-23) | 3.65% |
| 1 year (2023-07-21) | 20.78% |
|---|---|
| 2 years (2022-07-22) | 26.38% |
| 3 years (2021-07-23) | 46.89% |
| 5 years (2019-07-23) | 184.18% |
Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, AbbVie shares trade at around 51x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4488. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $26.1 billion.
The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $54.4 billion |
|---|---|
| Operating margin TTM | 28.29% |
| Gross profit TTM | $41.5 billion |
| Return on assets TTM | 7.71% |
| Return on equity TTM | 56.24% |
| Profit margin | 11.02% |
| Book value | $4.54 |
| Market Capitalization | $304.3 billion |
TTM: trailing 12 months
Dividend payout ratio: 55.93% of net profits
Recently AbbVie has paid out, on average, around 55.93% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.6% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 3.6% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $6.06 per share.
AbbVie's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
AbbVie's most recent dividend payout was on 14 August 2024. The latest dividend was paid out to all shareholders who bought their shares by 14 July 2024 (the "ex-dividend date").
Over the last 12 months, AbbVie's shares have ranged in value from as little as $132.1057 up to $179.5484. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.623. This would suggest that AbbVie's shares are less volatile than average (for this exchange).
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
A deep dive into the highlights and limitations of Frec.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.